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The genetic loss of endothelial-derived nitric oxide synthase
(eNOS) in mice impairs vascular endothelial growth factor (VEGF)
and ischemia-initiated blood flow recovery resulting in critical limb
ischemia. This result may occur through impaired arteriogenesis,
angiogenesis, or mobilization of stem and progenitor cells. Here,
we show that after ischemic challenge, eNOS knockout mice [eNOS
(ⴚ兾ⴚ)] have defects in arteriogenesis and functional blood flow
reserve after muscle stimulation and pericyte recruitment, but no
impairment in endothelial progenitor cell recruitment. More importantly, the defects in blood flow recovery, clinical manifestations of ischemia, ischemic reserve capacity, and pericyte recruitment into the growing neovasculature can be rescued by local
intramuscular delivery of an adenovirus encoding a constitutively
active allele of eNOS, eNOS S1179D, but not a control virus.
Collectively, our data suggest that endogenous eNOS-derived NO
exerts direct effects in preserving blood flow, thereby promoting
arteriogenesis, angiogenesis, and mural cell recruitment to immature angiogenic sprouts.

respond to vascular endothelial growth factor (VEGF). Indeed,
VEGF-mediated permeability, angiogenesis, and endothelial cell
precursor mobilization is markedly impaired in mice lacking eNOS
(10, 11, 16, 17). However, given the importance of eNOS in
regulating blood flow and arterial remodeling, it is possible that
other mechanisms are operational.
In this study, we show that eNOS is important for contractionevoked hyperemia in skeletal muscle, ischemia-mediated angiogenesis, and pericyte recruitment but not mobilization of endothelial
precursor cells into the systemic circulation. Moreover, local adenoviral gene delivery of a constitutively active allele of eNOS
(eNOS S1179D) rescues chronic limb ischemia in eNOS (⫺兾⫺)
mice, improves contraction induced hyperemia, lower limb angiogenesis, and pericyte recruitment, suggesting that the beneficial
autocrine and paracrine actions of eNOS-derived NO sustains
blood flow to severely ischemic limbs.
Methods
Mouse Hindlimb Ischemic Model and Adenovirus Gene Delivery. All

I

schemia-induced arteriogenesis and subsequent angiogenesis are
compensatory mechanisms to provide blood supply to ischemic
tissues. In the coronary circulation and peripheral vasculature,
ischemia-initiated opening of preexistent collaterals and arterialization of these immature vascular channels preserves blood flow
and contributes to the extent of ischemic reserve capacity in the
heart and leg (1). Therefore, understanding the molecular mechanisms of ischemia-initiated vascular remodeling and angiogenesis
is important.
The availability of knockout mice that are developmentally
‘‘normal’’ permits testing of genes required for postnatal hindlimb
angiogenesis and remodeling, despite their relative lack of importance during vasculogenesis. Examples of impaired ischemic limb
arteriogenesis and angiogenesis can be found in mice deficient in
placental-derived growth factor (2), IL-10 (3), the angiotensin II
type-1 receptor (4), matrix metalloproteinase-9 (5), adiponectin (6),
caveolin-1 (7), and, in some, but not all laboratories, the receptor
for monocyte chemotactic peptide 1, CC-chemokine receptor 2 (8,
9). One downstream pathway shown by multiple groups to be
important for ischemia-mediated arteriogenesis and blood flow
stimulated angiogenesis in endothelial nitric oxide synthase. In
many laboratories, endothelial-derived nitric oxide synthase
(eNOS) is required for postischemic blood flow recovery, because
mice deficient in eNOS show a severe form of critical limb ischemia
in mouse hindlimb models (10, 11). Moreover, the ability of,
statin-based drugs, angiotensin II, neuropeptide Y, and stromal
cell-derived factor-1␣ to improve limb angiogenesis are absent in
mice deficient in eNOS (12–15). The molecular mechanisms for
how eNOS regulates ischemia-triggered arteriogenesis and angiogenesis is related, in part, to the inability of eNOS (⫺兾⫺) mice to
www.pnas.org兾cgi兾doi兾10.1073兾pnas.0501444102

animal studies were approved by the institutional animal care and
use committees of Yale University. Eight- to 12-week-old male
congenic (F10) eNOS (⫺兾⫺) or C57BL兾6 mice (The Jackson
Laboratory, Bar Harbor, ME) were used for all experiments.
Mouse ischemic hindlimb model was performed as described in ref.
18 and detailed in Supporting Methods, which is published as
supporting information on the PNAS web site.
Blood Flow Measurement and Clinical Score. Blood flow was mea-

sured by the PeriFlux system with the Laser Doppler perfusion
module unit (Perimed, North Royalton, OH). A deep measurement
probe was placed directly on the gastrocnemius muscle to ensure a
deep muscle flow measurement. Ischemic and nonischemic limb
perfusion was measured before surgery, immediately after surgery,
and 3 days, 2 weeks and 4 weeks after surgery. The final blood flow
values were expressed as the ratio of ischemic to nonischemic hind
limb perfusion. To more precisely evaluate the mobility of mice
after limb ischemia, we designed a scoring system. 0 ⫽ normal; 1 ⫽
pale foot or gait abnormalities; 2 ⫽ gangrenous tissue in less than
one-half of the foot without lower limb necrosis; 3 ⫽ gangrenous
tissue in less than one-half of the foot with lower limb necrosis; 4 ⫽
gangrenous tissue in greater than one-half of the foot; 5 ⫽ loss of
one-half of the lower limb. Clinical outcome of all mice were
observed and recorded at the same time points of blood flow
measurement.
This paper was submitted directly (Track II) to the PNAS office.
Abbreviations: eNOS, endothelial NOS; EPC, endothelium progenitor cell; PDGF, plateletderived growth factor; SMA, anti-smooth muscle ␣ actin; VEGF, vascular endothelial
growth factor.
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Fig. 1. eNOS (⫺兾⫺) mice are a model of critical
limb ischemia with impaired hyperemia. (A and B)
C57BL兾6 or congenic eNOS (⫺兾⫺) mice were exposed to sham surgery (squares) or surgical arteriectomy (triangles) and gastrocnemius blood flow
(A) and clinical score (B) assessed over 4 weeks. (C)
The adductor muscle groups of mice were electrostimulated, and the increase in gastronemius blood
flow was recorded. (D) The identical experiment
was performed after 2 weeks of ischemia in
C57BL兾6 and eNOS (⫺兾⫺) mice. Data represent
mean ⫾ SEM; n ⫽ 4 mice per group for sham
surgery and n ⫽ 10 mice per strain for arteriectomy
in A and B; n ⫽ 5 mice per strain in C and D; *,
P ⬍ 0.05.

Postcontraction Hyperemia Before and After Schemia. After anes-

thesia, mice were placed on a heated pad. The adductor muscle
group and gastrocnemius muscle were exposed by a middle-line
incision of the limb. After baseline gastrocnemius blood flow was
measured, adductor muscles were stimulated with two electrodes at
2 Hz and 5 mA by using the electrostimulator for 2 min. Blood flow
was taken and recorded by MACLAB CHART (ADInstruments,
Grand Junction, CO) during stimulation and for 10 min after
stimulation.
Histology and Immunohistochemistry. Mice were killed at 4 weeks
after surgery, and muscles of the lower limbs were harvested,
methanol fixed, and paraffin embedded. Tissue sections (5-m
thick) were stained by using anti-PECAM-1 antibody (Pharmingen) and anti-smooth muscle ␣ actin (SMA) antibody (DAKO).
Bound primary antibodies were detected by using avidin-biotinperoxidase (NovaRed peroxidase substrate kit, Vector Laboratories) as described in Supporting Methods.
Gene Expression in Ischemic Muscle. Total RNA of lower limb

muscles was isolated by using phenol兾chloroform and isolated by
using RNeasy kit with DNase I digestion (Qiagen, Valencia, CA).
Reverse transcription was done by the standard procedure (Super
Script First-Strand Synthesis System, Qiagen) by using 1 g of total
RNA. Quantitative real-time PCR was performed as described in
Supporting Methods.
Arteriogenesis Analysis. Two and 4 weeks after surgery, mice were

anesthetized and heparinzed. Mice were perfused with PBS containing the vasodilators (papaverine, 4 mg兾liter; adenosine, 1
g兾liter) for 3 min at physiological pressure through descending
aorta, and blood was drained from the inferior vena cava. The
vasculature was fixed with 2% paraformaldehyde (in PBS) for 5
min, flushed with PBS for 2 min, and infused with contrast agent
(bismuth oxychloride in saline and 10% gelatin in PBS, 1:1). Mice
were then immersed in ice to solidify the contrast agent. Microangiography was taken with Faxitron x-ray machine (Hewlett–
Packard) at 25 kV and 3.25 mA for 3 min. Upper limb vascular
density (pixel density), vessel length (average length of vessels with
diameter ⬎1 pixel), and fractal dimension were analyzed by mod11000 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0501444102

ified IMAGEJ and MATLAB software (Research Services Branch,
National Institute of Mental Health, Bethesda, MD).
Endothelium Progenitor Cell (EPC) Mobilization Assay. After anesthesia and heparinization, blood was drawn by cardiac puncture.
Mononuclear cells were isolated by a density gradient method by
using Histopaque-1077 (Sigma). Five hundred microliters of blood
was mixed with 2 ml of PBS, gently added to 2 ml of Histopaque1077, and centrifuged at 400⫻ g for 30 min. The mononuclear
fraction was collected, washed in PBS, and following red cell lysis
with ammonium chloride solution (StemCell Technologies), 1 ⫻
106 cells per cm2 were seeded on fibronectin-coated slides (Clontech). Cells were allowed to differentiate in EGM-2 SingleQuots
medium (Cambrex, East Rutherford, NJ) containing VEGF-A,
FGF, IGF-1, hydrocortisone, ascorbic acid, GA 1000, heparin, 1%
gentamicin兾streptomycin (GIBCO, Carlsbad, CA), and 5% FBS.
Medium was changed every other day. After 5 days of in vitro
culture, cells were incubated in 10 g兾ml Ac-Dil-LDL (Biomedical
Technologies) for 4 h and Ac-Dil-LDL-positive cells were photographed and counted in 10 low power (10⫻) fields for each animal.
Statistical Analysis. All data are expressed as means ⫾ SEM.
Statistical differences were measured by either Student’s t test or
one or two-way analysis of variance followed by Bonferroni post hoc
test. A value of P ⬍ 0.05 was considered as statistically significant.

Results
eNOS Deficiency Results in Impaired Blood Flow Recovery, Severe
Limb Ischemia, and Impaired Ischemic Reserve Capacity. Surgical

arteriectomy of the left femoral artery in congenic eNOS (⫺兾⫺)
mice results in a severe form of limb ischemia. As seen in Fig. 1A,
before surgery (BS), the ratio of left leg to right leg gastrochemius
blood flow by using a deep penetrating laser Doppler applied
directly to the muscle is 1. Postsurgery (PS), flow drops by 80% in
both C57BL兾6 and eNOS (⫺兾⫺) mice and, in C57BL兾6 mice,
returns to a ratio of 1 over the ensuing 4 weeks. In contrast, there
is a marked impairment in gastrocnemius blood flow in eNOS
(⫺兾⫺), consistent with previous studies measuring superficial
blood flow through laser Doppler perfusion imaging (10, 11). The
Yu et al.

area and length in the adductor regions of interest (Fig. 2 B and C).
The increase in total arterial dimensions was not due to changes in
branching patterns because the fractal dimensions were similar on
the right and left legs (fractal dimension for C57BL兾6 mice were
1.52 on the ischemic leg and 1.46 in the contralateral leg). In
contrast, ischemia did not increase vascular density or length to the
same extent in eNOS (⫺兾⫺), documenting for the first time an
impairment in arteriogenesis in these mice (2 A Right as quantified
in B and C). Again, the changes in arterial dimensions were not due
to changes in branching patterns as the fractal dimensions were
similar on the right and left legs [fractal dimension for eNOS (⫺兾⫺)
were 1.40 in the ischemic leg and 1.52 in the contralateral leg].
These data document the impaired arteriogenesis in eNOS (⫺兾⫺)
mice but no gross changes in vascular patterning.
Postischemic Angiogenesis, Recruitment of Pericytes, and Gene Expression Is Impaired in eNOS (ⴚ兾ⴚ) Mice. Secondary to upper limb

impairment in blood flow in eNOS (⫺兾⫺) is associated with a
marked increase in clinical severity (Fig. 1B).
The above data suggests that eNOS (⫺兾⫺) may lack the ability
to use preexisting collaterals to supply blood flow to the lower leg
secondary to ischemia. To assess the capacity to recruit blood flow
through preexisting collaterals to ischemic tissue, we examined
skeletal muscle contraction-stimulated hyperemia in the gastrocnemius muscle in C57BL兾6 and eNOS (⫺兾⫺) mice at baseline and
after ischemia. Electrical stimulation of the adductor muscle groups
in the upper legs of C57BL兾6 (squares) and eNOS (⫺兾⫺; triangles)
mice results in a marked increase in peak blood flow measured in
the gastrocnemius muscle group of both strains [compare before
stimulation (PreSti) to time 0, Fig. 1C]. However, the return to
baseline flow is markedly accelerated in eNOS (⫺兾⫺) mice compared with C57BL兾6 mice, suggesting that eNOS-derived NO is
critical for maintaining vasodilation necessary for the gradual
return of flow back to normal. Next, we measured the same
physiological response after limb ischemia in C57BL兾6 and eNOS
(⫺兾⫺) mice at 1 and 2 weeks after ischemia. At 1 week after
ischemia, despite a return of resting blood flow in the gastrocnemius
in C57BL兾6 mice (see Fig. 1 A), we were unable to measure a
hyperemic response in both strains (data not shown). However,
after 2 weeks of ischemia, electrical stimulation of the adductor
muscle groups in the upper leg resulted in a 60% increase in peak
blood flow measured in the gastrocnemius muscle group of
C57BL兾6 mice and a markedly diminished peak response in eNOS
(⫺兾⫺) mice (⬇20%, Fig. 1D). The kinetics of blood flow recovery
after hyperemia were similar in ischemic C57BL兾6 mice compared
with their nonischemic counterparts, an effect dramatically attenuated in eNOS (⫺兾⫺) mice. These data show that nonischemic
eNOS (⫺兾⫺) mice have a normal peak hyperemic response but
reduced blood flow after stimulation and ischemic eNOS (⫺兾⫺)
mice have markedly reduced flow both during and after stimulation.
Postischemic Arteriogenesis Is Impaired in eNOS (ⴚ兾ⴚ) Mice. Next, we

examined ischemia-initiated arteriogenesis in C57BL兾6 and eNOS
(⫺兾⫺) mice by quantitative angiography. As seen in Fig. 2A, after
4 weeks of ischemia in C57BL兾6 mice (left panel), there was an
increase in tracer perfusion on the ischemic side (Left) compared
with the contralateral leg, reflecting an increase in the density and
length of vessels. This result was quantified as an increased vessel
Yu et al.

Adenoviral Delivery of Constitutively Active eNOS Rescues Limb
Ischemia in eNOS (ⴚ兾ⴚ) Mice. To examine whether local gene

delivery of eNOS could rescue the critical limb ischemia in eNOS
(⫺兾⫺) mice, we used a constitutively active form of eNOS bearing
a mutation of a key phosphorylation site, Serine 1179 to an
aspartate residue (Ad-eNOS S1179D). Serine 1179 is phosphorylated by several kinases including AMPK, Akt, PKG, and PKA, and
phosphorylation of this residue increases the basal synthesis of NO
(19, 20). Moreover, substitution of aspartate for serine mimics the
negative charge imparted by the phosphate and renders eNOS
constitutively active by increasing the rate of electron flux through
PNAS 兩 August 2, 2005 兩 vol. 102 兩 no. 31 兩 11001
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Fig. 2. Angiographic evidence for impaired arteriogenesis in eNOS (⫺兾⫺)
mice. (A) Arterial phase angiograms from C57BL兾6 (Left) and eNOS (⫺兾⫺)
(Right) mice after 4 weeks of left limb ischemia. (B and C) eNOS (⫺兾⫺) mice
show reduced quantification of vessel area (B) and total length (C) compared
with C57BL兾6 mice. Data are mean values from two angiograms.

ischemia, shear stress-dependent changes in blood flow promotes
capillary angiogenesis in the lower leg. As seen in Fig. 3A, after 4
weeks of ischemia, there was an increase in PECAM-1-positive
endothelial cells surrounding the skeletal muscle myocytes in
C57BL兾6, an effect markedly diminished in eNOS (⫺兾⫺) mice (as
quantified in Fig. 3B). Stable angiogenesis is believed to occur
contemporaneously with pericyte recruitment mediated by plateletderived growth factor (PDGF) and兾or angiopoietin-1. To examine
the recruitment of pericytes to angiogenic capillary sprouts after
ischemia, thin, serial sections were immunostained with PECAM-1
or SMA antibodies. As seen in Fig. 3 C and D, ⬇25% of PECAM1-positive skeletal muscle capillaries and vessels were colabeled
with SMA in cross sections of ischemic gastrocnemius muscles from
C57BL兾6 mice. In contrast, 5% of PECAM-1-positive structures
colabeled with SMA in gastrocnemius muscles from eNOS (⫺兾⫺)
mice. Next, we examined the difference in gene expression of
several growth factors and their cognate receptors implicated in
angiogenesis and pericyte recruitment by using quantitative PCR.
The levels of gene expression were compared in ischemic and
contralateral, nonischemic gastrocnemius muscle groups 3 days and
2 weeks after ischemia in both strains of mice. As seen in Fig. 3E,
a value of 1 reflects the normalized level of gene expression in
nonsurgically manipulated muscles (comparing left with right leg).
After 3 days of ischemia, the levels of VEGF isoforms (VEGF-A,-B
and –C) were 2- to 3-fold higher in C57BL兾6 mice; however, the
levels of the genes for VEGF receptors (Flk-1, Flt-1) were not
different. Angiopoeitin-1 (Ang-1) and its receptor Tie-2 were
slightly increased, whereas angiopoeitin-2 (Ang-2) levels were
similar. The genes for PDGF-A and -B chains and the PDGF-␣
receptor (PDGFR-␣) did not change. However, there was a marked
increase in PDGF-␤ receptor (PDGFR-␤) gene expression. After
2 weeks of ischemia (Fig. 3F) in C57BL兾6 mice, VEGF isoform
levels remained elevated and, in particular, VEGF-B was markedly
increased in C57BL兾6 mice compared with eNOS (⫺兾⫺) mice. The
levels of the VEGF receptor Flt-1 also were higher. All other genes
remained remarkably consistent. Collectively, these data suggest
both the impaired ischemia driven angiogenesis and immature,
SMA deficient vessels in eNOS (⫺兾⫺) mice correlates with reductions in the mRNAs for both VEGF and PDGF signaling pathways.

Fig. 3. Impaired ischemia-induced angiogenesis, pericyte recruitment, and gene expression in eNOS (⫺兾⫺) mice. Gastrocnemius muscles of ischemic mice were
immunostained for PECAM-1 (an endothelial cell marker) only (A with quantification in B) or PECAM-1 and SMA (a smooth muscle兾pericyte marker in C with
quantification in D). Data represent mean ⫾ SEM; n ⫽ 8 mice per strain in B and D; *, P ⬍ 0.05. The expression of angiogenic and remodeling genes were assessed by
qPCR in the gastronemius after 3 days (E) and two weeks (F) after ischemia. Data represent the differences in gene expression in C57BL兾6 compared with eNOS (⫺兾⫺)
mice. Data are average determinations of relative gene expression in ischemic兾nonischemic limbs from RNA pooled from three mice per strain per time point.

the protein and increases basal NO production severalfold (21). The
delivery method and activity of this construct has been well
characterized (22–24). As seen in Fig. 4A, intramuscular injection
Ad-eNOS S1179D into the adductor muscle group of ischemic
eNOS (⫺兾⫺) resulted in expression of eNOS (detected at 4 days
after infection by immunofluoresence microscopy) in the sarcolemma of myocytes and in adjacent vasculature (Right), whereas
injection of a control virus expressing Ad-GFP did not result in
eNOS labeling (Left). These data verify adenoviral delivery of
eNOS into cells in the adductor muscle group. Administration of
Ad-eNOS S1179D, but not Ad-GFP, into the adductor muscle
group of eNOS (⫺兾⫺) mice at the time of surgery markedly
improved blood flow recovery at 2 and 4 weeks after ischemia (Fig.
4B). Remarkably, the improvement of blood flow partially rescued
the severely ischemic limb (Fig. 4C), clinical scores (Fig. 4D), and
skeletal myocyte damage (Fig. 4E). More significantly, Ad-eNOS
S1179D partially rescued skeletal muscle contraction-stimulated
hyperemia in the gastrocnemius muscle (Fig. 4F), consistent with
eNOS gene transfer improving resting blood flow and clinical
outcome.
Ad-eNOS S1179D Gene Transfer Promotes Postischemic Angiogenesis
and Recruitment of Pericytes in eNOS (ⴚ兾ⴚ) but Does Not Effect EPC
Mobilization. Next, we examined capillary angiogenesis and pericyte

recruitment in eNOS (⫺兾⫺) transduced with Ad-eNOS S1179D or
Ad-GFP. Administration of Ad-GFP did not influence the number
of PECAM-1-positive vascular structures (Fig. 5A, third column) or
SMA positive, PECAM-1 positive, mature vessels in the gastrocnemius muscle (Fig. 5B). However, Ad-eNOS S1179D gene transfer
increased the number of PECAM-1-positive structures as well
SMA兾PECAM-1-positive structures. These data demonstrate that
11002 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0501444102

local delivery of eNOS is sufficient to rescue both the anatomical
and functional deficiencies in eNOS (⫺兾⫺) mice.
Previous work has demonstrated that basal numbers of circulating EPCs do not differ between eNOS (⫺兾⫺) and control mice.
However, after i.v. injection of VEGF, the mobilization of EPCs, as
isolated from the spleen, is markedly impaired in eNOS (⫺兾⫺)
mice, suggesting that eNOS influences the recruitment of EPCs. In
addition, the defect in hindlimb flow recovery in ischemic eNOS
(⫺兾⫺) mice could be rescued by i.v. infusion of in vitro expanded
EPCs (11) but not wild-type bone marrow, suggesting that progenitor cells mobilization from bone marrow is impaired in eNOS
(⫺兾⫺) mice. However, there are no data examining ischemiamediated mobilization of EPCs into the blood in eNOS (⫺兾⫺)
mice. Therefore, we assessed whether endogenous eNOS and兾or
local delivery of Ad-eNOS S1179D influences ischemia-mediated
peripheral EPC mobilization into peripheral blood. In contrast to
defects in VEGF-stimulated mobilization of splenic EPCs seen in
eNOS (⫺兾⫺) mice, limb ischemia triggered similar levels of EPC
mobilization in C57BL兾6 and eNOS (⫺兾⫺) mice (Fig. 5C). Moreover, intramuscular delivery of Ad-GFP or Ad-eNOS S1179D did
not modify ischemia-induced mobilization of peripheral EPCs in
eNOS (⫺兾⫺) mice (Fig. 5D). These data indicate that the improved
structural and functional recovery in eNOS (⫺兾⫺) mice administered with Ad-eNOS S1179D is unlikely related to an effect on EPC
mobilization but to the local actions of eNOS-derived NO on blood
flow, angiogenesis, and vessel maturation.
Discussion
The most salient findings of this study are that eNOS (⫺兾⫺) have
a defective postcontraction hyperemic response at rest and exhibit
a severe form of limb ischemia due to impaired ischemic flow
reserve, arteriogenesis, angiogenesis, and pericyte stabilization of
Yu et al.

angiogenic vasculature; defects consistent with impairments of gene
expression for components of VEGF and PDGF pathways. Remarkably, most of these functional and structural defects can be

Fig. 5. Ad-eNOS S1179D improves angiogenesis but does not influence EPC
mobilization. Gastrocnemius muscles of ischemic C57BL兾6, eNOS (⫺兾⫺), and
eNOS (⫺兾⫺) mice injected with Ad-GFP or Ad-eNOS S1179D were immunostained for PECAM-1 (an endothelial cell marker) (A) or serial sections colabeled with PECAM-1 and SMA antibodies (a smooth muscle兾pericyte marker)
(B). Ischemia mediated increases in EPC mobilization into peripheral blood in
C57BL兾6 and eNOS (⫺兾⫺) mice (C), and the beneficial effects of Ad-eNOS
S1179D (D) are not different. Data are mean ⫾ SEM; n ⫽ 5 mice per treatment
in A, B, and D and 6 mice per group in C; *, P ⬍ 0.05.
Yu et al.

rescued by local delivery of an adenovirus expressing a constitutively active form of eNOS. A priori, correction of the severe limb
ischemia exhibited in eNOS (⫺兾⫺) with Ad-eNOS S1179D (this
study) but not VEGF [protein or adenovirus (10), statins (13), or
SDF-1␣ (15)] argues in favor of eNOS-derived NO as a critical
second messenger and paracrine mediator of adaptive arteriogenesis and angiogenesis during limb ischemia in mice.
Ischemia-triggered arteriogenesis is believed to mediate a series
of factors including monocyte兾macrophage derived cytokines, such
as monocyte chemotactic peptide 1 or VEGF, followed by changes
in shear stress in preexisting collaterals that would activate eNOS
acutely and induce its gene expression after chronic changes in
blood flow as seen during exercise training (1, 25). eNOS-derived
NO can serve in its well known capacity as a vasodilator to reduce
vascular resistance, improve blood flow, and maintain proportional
remodeling of blood vessels during changes in blood flow (26). In
addition, eNOS exerts a second messenger role in VEGF signaling
and is necessary for many of the actions of VEGF in cultured
endothelial cells or in postnatal mice (27–29). Most directly, work
from several laboratories has shown that VEGF-induced angiogenesis, vascular leakage, and EPC isolation from spleen are dramatically reduced in eNOS (⫺兾⫺) mice or by NOS inhibitors in normal
mice (10, 11, 16, 17). The relevance of the VEGF兾NO link has been
manifested clinically because a primary side effect in cancer patients treated with anti-VEGF therapy is hypertension, likely due to
a deficit in VEGF coupling to eNOS activation and NO release
(30). Once formed, NO can positively and negatively regulate the
synthesis of VEGF depending on the levels of NO produced and
oxygen tensions (31–34). Our data support the idea that eNOSderived NO promotes VEGF production because VEGF isoform
mRNA levels were reduced in ischemic limbs from eNOS (⫺兾⫺)
mice compared with wild-type mice. Whether this occurs as a direct
or indirect consequence of NO in vivo is not known. Collectively,
these data support multiple links between eNOS and VEGF
signaling pathways but are in stark contrast to the lack of importance of eNOS during vascular development compared with the
PNAS 兩 August 2, 2005 兩 vol. 102 兩 no. 31 兩 11003
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Fig. 4. Intramuscular injection of Ad-eNOS S1179D, rescues ischemic defect in flow, clinical outcome, and hyperemia. (A) eNOS (⫺兾⫺) mice were injected with
Ad-GFP or Ad-eNOS S1179D and eNOS levels examined in the adductor muscle group by fluorescence microscopy after 4 days of infection. (Scale bars: Upper Left,
200 m; Lower Left, 50 m.) Ad-eNOS S1179D improved the time course of blood flow recovery (B) and clinical outcome (D). Images in C and E reflect improvement
of limb appearance and muscle histology after Ad-eNOS S1179D infection. (F) Ad-eNOS S1179D gene transfer into eNOS (⫺兾⫺) mice also improves postcontraction hyperemia. Data are mean ⫾ SEM; n ⫽ 5 mice per group in B, D, and F; *, P ⬍ 0.05.

essential role for VEGF and its receptors. eNOS (⫺兾⫺) mice have
smaller litter sizes but do not exhibit gross defects in vasculogenesis
(35, 36), whereas genetic loss of VEGF164 or its receptors in mice
triggers defects in embryonic vasculogenesis and angiogenesis. This
paradox provides an important example demonstrating that genes
required for embryonic vascular patterning or angiogenesis may
overlap but also differ from those used in postnatal paradigms of
angiogenesis. Our data showing the essential role of eNOS for
various aspects of ischemic arteriogenesis兾angiogenesis and the
rescue of ischemic defects by reintroduction of eNOS provides a
solid, genetic argument supporting the critical role of eNOS.
Although cytokines are implicated as initiators of ischemic
arteriogenesis and angiogenesis, the role of mechanical forces and
shear stress in shaping and兾or remodeling growing collaterals or
capillaries should not be underestimated. Clearly, in adult mice,
changes in blood flow, in the absence of overt changes in inflammatory cytokines, are sufficient to remodel large conduit and
resistance blood vessels and promote capillary angiogenesis (37,
38). Similar evidence for flow-mediated remodeling and arterialization is beginning to be embraced as a determinant of vascular
patterning during vasculogenesis (39, 40). The role of eNOS in
flow-regulated, noninflammatory angiogenesis has been shown
because the genetic loss of eNOS attenuated flow mediated increases in capillary to fiber ratio in certain muscle groups (41). Our
data supports the importance of flow as an important regulator of
ischemic arteriogenesis and angiogenesis, because we detected a
subtle defect in blood flow after stimulation in nonischemic eNOS
(⫺兾⫺) mice, akin to endothelial dysfunction, and a grossly impaired
ischemia initiated blood flow reserve capacity in ischemic eNOS
(⫺兾⫺) mice. We interpret these data as follows: after ischemic
challenge, eNOS (⫺兾⫺) mice lack the ability to redirect blood flow
through preexisting collaterals (through impaired downstream vasodilation), thereby reducing shear dependent remodeling of collaterals and the attendant lower limb angiogenesis. The reduction
in flow reduces shear stress-dependent eNOS activation and sub-

sequent NO release, thus retarding further growth of the collaterals
and flow-dependent angiogenesis and remodeling of angiogenic
sprouts in the lower limb. At the same time, it is clear the eNOS
(⫺兾⫺) mice are defective in their responses to exogenous VEGF
and SDF-1 (10, 11, 15), two cytokines implicated in ischemic
remodeling, angiogenesis, and mobilization of bone marrow endothelial progenitor cells; however, in our hands, ischemia triggered
mobilization of EPCs into peripheral blood were not different
between wild-type and eNOS (⫺兾⫺) mice. Moreover, we can
partially correct defects in arteriogenesis, angiogenesis, and limb
ischemia by adenoviral eNOS S1179D into eNOS (⫺兾⫺) mice
without affecting ischemia-triggered EPC mobilization. Considering that a majority of the adenovirally transduced cells are myocytes, we interpret the functional recovery after gene transfer to a
bystander effect, i.e., NO diffusion from the site of synthesis to
adjacent vasculature to improve flow reserve and shear-dependent
remodeling and angiogenesis.
Collectively, our data strongly support the role of eNOS-derived
NO as a critical gene in regulating many aspects of blood flow
control and a second messenger for pathways leading arteriogenesis
and stable angiogenesis. Considering the prevalence of endothelial
dysfunction (manifested by impaired eNOS兾NO bioavailability)
associated with aging, cardiovascular diseases, and peripheral vascular insufficiency, our results imply that therapeutic approaches
aimed at improving arteriogenesis in patients with peripheral
vascular disease by using a single cytokine will have limited utility
unless impairments in eNOS function are taken into account and
corrected.
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